{"id":738,"date":"2017-02-14T08:19:09","date_gmt":"2017-02-14T07:19:09","guid":{"rendered":"http:\/\/intervacc.se\/en\/?page_id=738"},"modified":"2022-12-19T10:52:49","modified_gmt":"2022-12-19T09:52:49","slug":"a-new-generation-of-vaccines-within-animal-health","status":"publish","type":"page","link":"https:\/\/intervacc.se\/en\/","title":{"rendered":"A new generation of vaccines within animal health"},"content":{"rendered":"<div class=\"preamble\">Intervacc AB is a Swedish company active in the biotechnology sector.\u00a0We develop new vaccines based on fusions of recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.<\/div>\n<p><a href=\"\/en\/research\/pipeline\/strangvac\/\"><img loading=\"lazy\" class=\"alignone wp-image-2312 size-full\" style=\"margin: -5px 13px 5px 12px;\" src=\"\/wp-content\/uploads\/2022\/09\/strangvac-vaccine.jpg\" alt=\"Strangvac - our strangles vaccine project\" width=\"176\" height=\"152\" \/><\/a><a href=\"\/en\/research\/pipeline\/inv-274\/\"><img loading=\"lazy\" class=\"alignnone wp-image-2313 size-full\" style=\"margin: -5px 13px 5px 13px;\" src=\"\/wp-content\/uploads\/2020\/04\/2-INV274.jpg\" alt=\"INV274 a vaccine candidate against infections caused by Strep suis \" width=\"176\" height=\"152\" \/><\/a><a href=\"\/en\/research\/pipeline\/novel-antigen\/\"><img loading=\"lazy\" class=\"alignone wp-image-2314 size-medium\" style=\"margin: -5px 11px 5px 13px;\" src=\"\/wp-content\/uploads\/2020\/04\/3-INV412.jpg\" alt=\"INV412 a vaccine candidate against mastitis caused by Staph aureus\" width=\"176\" height=\"152\" \/><\/a><\/p>\n<p>Together with our two subsidiaries Nordvacc L\u00e4kemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health and welfare.\u00a0Here you can find more about the Group&#8217;s <a href=\"http:\/\/intervacc.se\/en\/products-services\/\">products and services<\/a> our <a href=\"\/en\/research\/\">project portfolio<\/a> for a new generation of vaccines against bacterial infections.<\/p>\n<ul class=\"list-style\">\n<li>Intervacc&#8217;s subsidiary company Nordvacc have over 30 years&#8217; experience in the veterinary vaccines market, serving the Nordic, Dutch and Baltic markets with more than 200 million doses sold<\/li>\n<li>The <a href=\"http:\/\/intervacc.se\/en\/research\/recombinant-technology\/\">technology platform<\/a> is based on research from the Karolinska Institute and the\u00a0Swedish University of Agricultural Sciences<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Intervacc AB is a Swedish company active in the biotechnology sector.\u00a0We develop new vaccines based on fusions of recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Together with our two subsidiaries Nordvacc L\u00e4kemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false},"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/738"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=738"}],"version-history":[{"count":25,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/738\/revisions"}],"predecessor-version":[{"id":504530,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/pages\/738\/revisions\/504530"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}